Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 0%
Sell 10%
Strong Sell 0%

Bulls say

Sionna Therapeutics is well-positioned for success in the cystic fibrosis market, with a promising drug candidate in SION-719 and a strong financial position. However, the reliance on third-party suppliers and the recent production delays may present challenges in the future. Overall, the company's focus on developing CFTR modulators and addressing the most common mutation in CF patients is a positive outlook for their potential impact on the treatment of cystic fibrosis.

Bears say

Sionna Therapeutics is a clinical-stage biotech company that aims to develop novel medicines for the treatment of cystic fibrosis, and while their management team holds extensive experience, there are risks associated with development delays and a complete pipeline termination. Notably, the company's SION-719 drug has shown promising results in preclinical studies and phase 1 trials, but it will be important for them to maintain development timelines in order to reach their target price of $53 per share. The company's other drug, SION-451, has shown positive results in stabilizing CFTR, but recruitment delays or a longer development campaign could impact its success. Overall, the company's focus on targeting NBD1 to restore CFTR function offers potential for success, but the risks should be carefully considered before investing.

SION has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 10 analysts, SION has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.